BioCentury | Feb 13, 2019
Distillery Therapeutics

Cancer

...of other solid tumors and hematologic malignancies. Apogenix AG and Canbridge Life Sciences Ltd. have asunercept...
BioCentury | Apr 13, 2018
Clinical News

China FDA approves IND for Canbridge's GBM candidate

...said China FDA approved an IND to begin a Phase II/III trial of asunercept (APG101, CAN-008...
...BioCentury that Canbridge plans to dose the first patient in the trial later this year. Asunercept...
...Sciences Ltd., Beijing, China Product: Asunercept (APG101, CAN-008) (formerly Apocept) Business: Cancer Sandi Wong asunercept (APG101, CAN-008, apocept) Apogenix...
BioCentury | Sep 29, 2017
Strategy

Bridge to innovation

...using Boston as a hub,” he said. Canbridge’s lead program is asunercept ( CAN-008 , APG101...
...a Phase II/III for GBM in China early next year. Canbridge has Chinese rights to asunercept...
BioCentury | Jul 13, 2017
Clinical News

Apogenix's asunercept receives PRIME designation for glioblastoma

...May, Apogenix AG (Heidelberg, Germany) said EMA granted PRIority MEdicines (PRIME) designation to asunercept (APG101, CAN-008...
...treat glioblastoma. The designation is based on data from a Phase II trial in which asunercept...
...Sciences Ltd. , Beijing, China Product: Asunercept ( APG101 , CAN-008) (formerly Apocept) Business: Cancer Alex Himes APG101 asunercept CAN-008 Apogenix...
BioCentury | May 23, 2017
Financial News

Lapam leads Canbridge's $25M series B

...develop the compounds in parallel with their Western counterparts. The company's lead candidates CAN008 ( APG101...
...regarding the timing of its ESCC clinical program (see BioCentury, March 28, 2016) . Jaime De Leon APG101 asunercept AV-203 CAN-008 CAN-017 Apogenix...
BioCentury | Oct 3, 2016
Clinical News

APG101: Phase I/II started

...Canbridge began a Taiwanese Phase I/II trial to evaluate once-weekly 200 and 400 mg IV CAN-008...
...Phase I portion are expected in 2H17. Canbridge has exclusive rights to develop and commercialize CAN-008...
...Heidelberg, Germany Canbridge Life Sciences Ltd. , Beijing, China Product: APG101 , CAN-008 (formerly Apocept...
BioCentury | Aug 8, 2016
Clinical News

APG101: Phase I/II start

...This month, Canbridge will begin a Phase I/II trial evaluating CAN-008 plus temozolomide in about 55...
...and a double-blind, placebo-controlled Phase II portion. Canbridge has exclusive rights to develop and commercialize CAN-008...
...Heidelberg, Germany Canbridge Life Sciences Ltd. , Beijing, China Product: APG101 , CAN-008 (formerly Apocept...
BioCentury | Aug 4, 2016
Distillery Therapeutics

Therapeutics: FAS receptor (CD95); CD95 ligand

...the CD95-mediated calcium signaling pathway. Apogenix AG and Canbridge Life Sciences Ltd. have APG101 ( CAN-008...
BioCentury | Jul 14, 2016
Product R&D

Apogenix's hex on TNF

...involved in various types of signaling pathways ranging from apoptosis to differentiation. Apogenix’s lead compound, APG101...
...Höger told BioCentury the concept behind HERA was discovered unexpectedly when company researchers were characterizing APG101...
BioCentury | Mar 28, 2016
Strategy

Canbridge can-can

...cancer patients. Last year, Apogenix GmbH granted Canbridge exclusive Chinese rights to develop and commercialize APG101...
Items per page:
1 - 10 of 35